✦ LIBER ✦

Salvage Therapy with Bevacizumab–Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

✍ Scribed by Jacques Medioni; Eugeniu Banu; Dominique Helley; Florian Scotte; Laure Fournier; Arnaud Mejean; Antoine Chedid; Michel Azizi; Jean-Marie Andrieu; Stéphane Oudard

Book ID: 113611262
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 527 KB
Volume: 56
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2009.01.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN42 COSTS OF MANAGING ADVERSE EVENTS O

PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO: BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB

✍ F Carlos; J Ramirez; A Aguirre 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Response to Sorafenib After Sunitinib-In

Response to Sorafenib After Sunitinib-Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature

✍ Michael K. K. Wong; Anthony Jarkowski III 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

Safety and efficacy of the combination o

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib

✍ Flaig, T W; Costa, L J; Gustafson, D L; Breaker, K; Schultz, M K; Crighton, F; K 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 351 KB

PUK17 Cost-Mimimization Analysis of Pazo

PUK17 Cost-Mimimization Analysis of Pazopanib Versus Sunitinib, Sorafenib and Bevacizumab+ Interferon á-2a for Patients With Metastatic Renal Cell Carcinoma

✍ M. Sura; S. Goryaynov; M. Avxentyeva; V. Omelyanovsky 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Costs of managing adverse events in the

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

✍ Mickisch, G; Gore, M; Escudier, B; Procopio, G; Walzer, S; Nuijten, M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 356 KB

Regarding: ‘Costs of managing adverse ev

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

✍ Porta, C 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB